Liftstream is an executive search recruitment company in the life sciences sector
eFFECTOR Therapeutics Secures New Series B Funding
eFFECTOR Therapeutics, an early-stage company focused on the discovery and development of small molecule cancer therapeutics in San Diego, has secured its Series B financing up to USD 56 million. The new funding came from Sectoral Asset Management, a new investor in the syndicate, as well as existing investors. Meanwhile, eFFECTOR Therapeutics appointed Maha Katabi, a partner from Sectoral, to its board of directors.
Top 5 Articles from Liftstream Blog in 2015
These are the 5 articles most viewed this year…so here is a recap for your to dive back in and read what you missed.
Bicycle Therapeutics raises $32m for oncology assets
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Astellas Ventures, Atlas Ventures, Bicycle Therapeutics, Cambridge Antibody Technology, Domantis, funding, London Biotech, One Nucleus, Oxford Biotech, Professor Christian Heinis, Rolf Gunther, Sir Greg Winter, SR One, SV Life Sciences, venture capital
Leave a comment
AM-Pharma raises 12.2m Euros
Authored by James Sheppard
Bellicum Pharma announces $55m in Series C Funding for Cancer Trials
Authored by James Sheppard
Immatics receives final 22m Euro Tranche of Series D funding
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged 2015, BioRN, finance, funding, Germany, IMA901, immatics, Munich Biotech, oncology, Paul Higham, phase III clincial studies, RCC, renal cell carcinoma, Series D, Wellington Partners, XPRESIDENT
Leave a comment
Gene Therapy Start-up AAVLife raises $12m
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged AAVLife, Amber Salzman, biotech cluster, Dr Helene Puccio, Dr Pierre Bougneres, Dr Ronald Crystal, France, Friedreich’s Ataxia, funding, gene-deleting therapy, GSK, INSERM, Nature Medicine, Paris, Pierre Aubourg, Versant Ventures
Leave a comment
Swedish biotech Oxthera raises $10m for Orphan Drug Development
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged biopharmaceutical, clinical development, finance, funding, Gentium, Jazz Pharma, Kidney Failure in enteric hyperoxaluria, KLS Partners, Kurma Partners, Mayo Clinic, Medicon Valley, Oxabact, Oxazyme, Oxthera, primary hyperoxaluria, Remi Droller, sweden
Leave a comment